Verici Dx plc
VRCI.L
London Stock Exchange0.38
GBp
- -
- -
Verici Dx plc
VRCI.L
(London Stock Exchange)
Recent
price
0.38
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Verici Dx plc is an immuno-diagnostics development company specializing in the development and commercialization of advanced prognostic and diagnostic tests for kidney transplant patients. The company offers a complementary suite of kidney transplant assays designed to provide personalized risk profiles and clinical insights throughout the transplant journey. Its core products include Clarava, a pre-transplant test that assesses the risk of early acute rejection; Tutivia, a post-transplant diagnostic that detects acute cellular rejection including subclinical rejection undetectable by current standard methods; and Protega, a liquid biopsy aimed at predicting the risk of fibrosis and long-term graft failure. Verici Dx operates primarily in the United Kingdom and the United States through its subsidiary Verici Dx Inc, serving clinicians and transplant patients to optimize transplant outcomes. Founded in 2020 and headquartered in Penarth, Cardiff, UK, Verici Dx has recently made significant operational advances including receiving College of American Pathology (CAP) accreditation for its laboratory in Franklin, Tennessee. The company secured a global licensing agreement with Thermo Fisher Scientific to commercialize its pre-transplant risk test, underlining a strategic expansion of its commercial footprint. Verici Dx also achieved Medicare coverage for its Tutivia test, enabling broader adoption across the US healthcare market. Additionally, it has undertaken equity fundraising efforts to accelerate commercial growth and expanded its product portfolio towards fibrosis assessment to offer an end-to-end testing platform covering the entire kidney transplant patient journey. Verici Dx’s operations focus on the healthcare diagnostics and research industry, targeting transplant centers, nephrologists, and immunologists. The company’s tests use RNA gene signature technology to generate precise biological data that guide personalized patient and organ response management. With its innovative testing platform and strategic partnerships, Verici Dx aims to establish a competitive advantage in the transplant diagnostics market by addressing unmet clinical needs and improving long-term patient outcomes in kidney transplantation across Europe and North America. These recent strategic developments and product launches reflect Verici Dx's transition from a primarily research-driven organization to a commercial-stage diagnostics company with growing market presence and clinical adoption. The company continues to enhance its technological capabilities and expand its commercial partnerships to drive sustainable growth in the immuno-diagnostics sector. Verici Dx employs around 15 to 18 staff as it focuses on expanding its clinical validation and market deployment capabilities.